| June 24, 2026 | Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 23, 2026 | KEYTRUDA® (pembrolizumab) | MRK | Topline readout | Advanced Hepatocellular Carcinoma | Completed | ClinicalTrials.gov |
| June 19, 2026 | WELIREG® (belzutifan) | MRK | PDUFA date | — | Approved | SEC 8-K Exhibit 99.1 |
| June 15, 2026 | pembrolizumab/vibostolimab (MK-7684A) | MRK | Primary completion | Carcinoma, Non-Small-Cell Lung | Completed | ClinicalTrials.gov |
| June 12, 2026 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 12, 2026 | Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 12, 2026 | WELIREG® (belzutifan) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 8, 2026 | KEYTRUDA® (pembrolizumab) | MRK | Topline readout | Colorectal Cancer | Completed | ClinicalTrials.gov |
| June 8, 2026 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Solid Tumors | Completed | ClinicalTrials.gov |
| June 8, 2026 | KEYTRUDA® (pembrolizumab) | MRK | Topline readout | Advanced Non-Small Cell Lung Cancer | Completed | ClinicalTrials.gov |
| June 5, 2026 | MK-1167 | MRK | Primary completion | Alzheimer Disease; Dementia | Withdrawn | ClinicalTrials.gov |
| June 1, 2026 | efinopegdutide (MK-6024) | MRK | Topline readout | — | Completed | ClinicalTrials.gov |
| April 30, 2026 | — | MRK | Earnings | — | Completed | SEC 8-K Exhibit 99.1 |
| April 28, 2026 | IDVYNSO (doravirine-islatravir) | MRK | PDUFA date | — | Approved | SEC 8-K Exhibit 99.1 |
| April 24, 2026 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Breast Neoplasms | Completed | ClinicalTrials.gov |
| April 24, 2026 | Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| April 21, 2026 | zilovertamab vedotin (MK-2140) | MRK | Primary completion | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Completed | ClinicalTrials.gov |
| April 20, 2026 | IDVYNSO (doravirine-islatravir) | MRK | FDA approval | — | Approved | FDA Novel Drug Approvals |
| April 9, 2026 | frespaciguat (MK-5475) | MRK | Primary completion | Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease | Completed | ClinicalTrials.gov |
| April 7, 2026 | KEYTRUDA® (pembrolizumab) | MRK | PDUFA date | — | Scheduled | SEC 8-K Exhibit 99.1 |
| April 2, 2026 | tulisokibart (PRA023) | MRK | Primary completion | Hidradenitis Suppurativa | Completed | ClinicalTrials.gov |
| March 12, 2026 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Lung Cancer; Non-Small Cell Lung Cancer | Completed | ClinicalTrials.gov |
| March 12, 2026 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Solid Tumor; Cutaneous Squamous Cell Carcinoma; Endometrial Cancer | Completed | ClinicalTrials.gov |
| March 5, 2026 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Carcinoma, Squamous Cell; Skin Neoplasms | Withdrawn | ClinicalTrials.gov |
| February 20, 2026 | MVASI® (bevacizumab) | MRK | PDUFA date | — | Scheduled | SEC 8-K Exhibit 99.1 |
| February 10, 2026 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 10, 2026 | Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 4, 2026 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Carcinoma, Renal Cell | Completed | ClinicalTrials.gov |
| February 4, 2026 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Carcinoma, Renal Cell | Completed | ClinicalTrials.gov |
| February 3, 2026 | — | MRK | Trial start | — | Completed | SEC 8-K Exhibit 99.1 |
| February 3, 2026 | — | MRK | Earnings | — | Completed | SEC 8-K Exhibit 99.1 |
| February 2, 2026 | WELIREG® (belzutifan) | MRK | Primary completion | Carcinoma, Renal Cell | Completed | ClinicalTrials.gov |
| January 27, 2026 | Noxafil (posaconazole) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 26, 2026 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Bladder Cancer | Completed | ClinicalTrials.gov |
| January 21, 2026 | Verquvo (vericiguat) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 21, 2026 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | — | Completed | ClinicalTrials.gov |
| January 14, 2026 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Hodgkin Lymphoma | Completed | ClinicalTrials.gov |
| December 29, 2025 | efinopegdutide (MK-6024) | MRK | Primary completion | Non-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLD | Completed | ClinicalTrials.gov |
| December 22, 2025 | V114 | MRK | Primary completion | Acute Otitis Media (AOM) | Completed | ClinicalTrials.gov |
| December 9, 2025 | Recarbrio (cilastatin sodium; imipenem; relebactam) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 21, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 21, 2025 | Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 20, 2025 | WINREVAIR (sotatercept) | MRK | Primary completion | Pulmonary Arterial Hypertension | Completed | ClinicalTrials.gov |
| November 5, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Bladder Cancer | Withdrawn | ClinicalTrials.gov |
| Nov 2025Month disclosed | IDVYNSO (doravirine-islatravir) | MRK | Topline readout | HIV-1 infection in previously untreated adults, and in November 2025, the Company | Positive | SEC Form 10-K |
| October 31, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Carcinoma, Non-Small-Cell Lung | Completed | ClinicalTrials.gov |
| October 30, 2025 | — | MRK | Earnings | — | Completed | SEC 8-K Exhibit 99.1 |
| October 27, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Bladder Cancer | Completed | ClinicalTrials.gov |
| October 25, 2025 | WINREVAIR (sotatercept) | MRK | PDUFA date | — | Scheduled | SEC 8-K Exhibit 99.1 |
| October 24, 2025 | Winrevair (sotatercept-csrk) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| October 16, 2025 | dor/isl (MK-8591A) | MRK | Primary completion | HIV Infection | Completed | ClinicalTrials.gov |
| October 15, 2025 | bla761495 | MRK | FDA approval | — | Approved | openFDA Drugs@FDA |
| October 14, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Triple Negative Breast Neoplasms | Completed | ClinicalTrials.gov |
| October 13, 2025 | dor/isl (MK-8591A) | MRK | Primary completion | HIV-1 Infection | Completed | ClinicalTrials.gov |
| September 23, 2025 | KEYTRUDA® (pembrolizumab) | MRK | PDUFA date | — | Scheduled | SEC 8-K Exhibit 99.1 |
| September 19, 2025 | Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) | MRK | FDA approval | — | Approved | FDA Novel Drug Approvals |
| September 3, 2025 | favezelimab/pembrolizumab (MK-4820A) | MRK | Primary completion | Hodgkin Lymphoma | Completed | ClinicalTrials.gov |
| Sep 2025Month disclosed | LIPFENDRA (enlicitide) | MRK | Topline readout | with hypercholesterolemia | Positive | SEC Form 10-Q |
| Sep 2025Month disclosed | MK-3475A | MRK | FDA approval | — | Approved | SEC 8-K Exhibit 99.1 |
| August 19, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Carcinoma, Hepatocellular | Withdrawn | ClinicalTrials.gov |
| August 12, 2025 | LYNPARZA® (olaparib) | MRK | Primary completion | Advanced Solid Neoplasms | Completed | ClinicalTrials.gov |
| August 5, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | — | Completed | ClinicalTrials.gov |
| July 30, 2025 | MK-6194 | MRK | Primary completion | Systemic Lupus Erythematosus | Withdrawn | ClinicalTrials.gov |
| July 29, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Advanced Hepatocellular Carcinoma | Completed | ClinicalTrials.gov |
| July 28, 2025 | Lipfendra (enlicitide decanoate) | MRK | Primary completion | Hypercholesterolemia; Familial Hypercholesterolemia | Completed | ClinicalTrials.gov |
| July 25, 2025 | — | MRK | Earnings | — | Completed | SEC 8-K Exhibit 99.1 |
| July 24, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 27, 2025 | efinopegdutide (MK-6024) | MRK | Primary completion | — | Completed | ClinicalTrials.gov |
| June 23, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Small Cell Lung Cancer | Completed | ClinicalTrials.gov |
| June 23, 2025 | cisplatin (DMS32212R) | MRK | PDUFA date | — | Scheduled | SEC 8-K Exhibit 99.1 |
| June 13, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Advanced Non-Small Cell Lung Cancer | Completed | ClinicalTrials.gov |
| June 10, 2025 | ENFLONSIA (clesrovimab) | MRK | PDUFA date | — | Scheduled | SEC Form 10-Q |
| June 9, 2025 | Enflonsia (clesrovimab-cfor) | MRK | FDA approval | — | Approved | FDA Novel Drug Approvals |
| June 6, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Urinary Bladder Cancer, Muscle-invasive | Completed | ClinicalTrials.gov |